FEATURED

Drug Showcase: ZELBORAF (vemurafenib)

Indicated for melanoma.

Chris Bakal: Big Data, Cancer Research

Cancer Therapy Advisor interviewed Dr Bakal about this new approach to analyzing cell shape and its potential to affect breast cancer treatment.

ASCO GU: Updates in Managing SRMs

At a general session at the 2017 ASCO GU Symposium, the latest advances in managing SRMs will be discussed.

ASCO GU 2017 Coverage

Our complete coverage of the ASCO Genitourinary Cancers Symposium 2017 meeting in Orlando.

Barriers to Progress for Bladder Cancer

At an education session at the 2017 GU Symposium experts will discuss some of the barriers to progress in the treatment of bladder cancer.

Explaining AR-indifferent Prostate Cancer

Physicians will speak about tumor evolution and AR-indifferent disease at the 2017 ASCO Genitourinary Cancers Symposium in Orlando, Florida.

Navigating the Costs of CML

The cost of treating CML can be crippling, and it's unclear whether future approvals or policies will improve the financial toxicity associated with the disease.

Weight Gain: A Risk Factor

While women who lost more than 5 kg after age 18 were at a 23% reduced risk for breast cancer, those who gained more than 30 kg were at a 32% increased risk.

Advance of the Year: Immunotherapy 2.0

The American Society of Clinical Oncology (ASCO) named Immunotherapy 2.0 the "advance of the year."

MM: Survival, Treatment Facility Volume

Patients who are treated for multiple myeloma at high-volume cancer centers have better survival outcomes than those receiving care at low-volume facilities.

For the treatment of metastatic non-small

Biomarker testing for epidermal growth factor receptor exon 19 deletions or exon 21 (L858R) substitution mutations is important when considering a first-line therapy

New Video Series: Classical Hodgkin Lymphoma

Steven M. Ansell, MD, PhD, of the Mayo Clinic in Rochester, Minnesota

Looking for a Job?

Access our job board to view over 1,​200 job openings throughout the US.

Treatment Regimens

A full listing of cancer treatment and drug information is available to access.

Latest Features

Q&A With Chris Bakal, PhD: Big Data and Cancer Cell-shape Research

Q&A With Chris Bakal, PhD: Big Data and Cancer Cell-shape Research

Cancer Therapy Advisor interviewed Dr Bakal about this new approach to analyzing cell shape and its potential to affect breast cancer treatment.

Explaining Androgen Receptor-indifferent Prostate Cancer

Explaining Androgen Receptor-indifferent Prostate Cancer

Physicians will speak about tumor evolution and AR-indifferent disease at the 2017 ASCO Genitourinary Cancers Symposium in Orlando, Florida.

2017 ASCO GU Symposium: Updates in Managing Small Renal Masses

2017 ASCO GU Symposium: Updates in Managing Small Renal Masses

At a general session at the 2017 ASCO GU Symposium, the latest advances in managing SRMs will be discussed.

Clinicians Address Barriers to Progress for Bladder Cancer

Clinicians Address Barriers to Progress for Bladder Cancer

At an education session at the 2017 GU Symposium experts will discuss some of the barriers to progress in the treatment of bladder cancer.

Navigating the Costs of Chronic Myeloid Leukemia: A Glimpse Into the Future

Navigating the Costs of Chronic Myeloid Leukemia: A Glimpse Into the Future

The cost of treating CML can be crippling, and it's unclear whether future approvals or policies will improve the financial toxicity associated with the disease.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters